The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of ...

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...

Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial ...

Novo Nordisk is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...

The company plans to create a new category of cellular medicines offering functional cures for metabolic and endocrine ...

A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...

Aspect Biosystems raises US$115 million in Series B funding to advance multiple bioprinted tissue therapeutics towards the ...

Vancouver-based Aspect Biosystems has raised a $115-million USD ($165 million CAD) Series B round to realize its ambitions of ...